MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-13-2025
Kamada Ltd. Total Non Current Liabilities 2011-2025 | KMDA
Annual Total Non Current Liabilities Kamada Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 7.06 M | 5.74 M | 2.17 M | 3.22 M | 5.75 M | 6.55 M | 7.7 M | 16.8 M | 31.5 M | 39.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.8 M | 2.17 M | 12.6 M |
Quarterly Total Non Current Liabilities Kamada Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 87.8 M | 8.32 M | - | - | 7.06 M | 6.42 M | - | - | 5.74 M | - | - | - | 2.17 M | - | - | - | 3.22 M | - | - | - | 5.75 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 87.8 M | 2.17 M | 15.8 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 4.89 | 3.82 % | $ 812 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
5.95 M | $ 3.22 | -1.08 % | $ 249 M |  USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
5 M | $ 1.07 | -5.31 % | $ 295 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
101 M | $ 213.6 | -3.09 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.1 | -5.53 % | $ 7.46 B |  Australia |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
62.5 K | $ 1.43 | -1.72 % | $ 2.11 M | USA |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
23.6 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
341 M | $ 93.97 | -0.89 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 26.35 | 4.25 % | $ 1.28 B | USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
26.1 M | $ 9.62 | 0.63 % | $ 141 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 0.26 | -8.44 % | $ 566 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
981 K | $ 13.28 | -5.78 % | $ 874 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
52.2 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
5.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
107 M | $ 550.6 | -2.43 % | $ 41.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
42.1 M | $ 2.37 | 3.04 % | $ 14.9 M | USA |
 |
AstraZeneca PLC
AZN
|
30.8 B | $ 91.34 | 1.68 % | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
17.3 M | $ 27.0 | -1.85 % | $ 1.74 M | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
374 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
802 M | $ 11.3 | -2.04 % | $ 731 M | USA |
 |
Biogen
BIIB
|
9.03 B | $ 175.09 | 0.57 % | $ 25.5 B | USA |
 |
Abeona Therapeutics
ABEO
|
6.69 M | $ 5.07 | -5.5 % | $ 108 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
2.29 M | $ 87.9 | -0.1 % | $ 9.07 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
648 K | $ 24.31 | 2.92 % | $ 2.88 B | USA |
 |
ADiTx Therapeutics
ADTX
|
858 K | $ 1.6 | -28.57 % | $ 21.1 K | USA |
 |
Cellectar Biosciences
CLRB
|
422 K | $ 3.33 | -8.01 % | $ 40.7 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
48 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |